Our data suggested that HGF-MET signaling pathway was likely to be overactivated in ESCC, representing a potential therapeutic target, but eligibility for this therapy should consider intratumor heterogeneity. The gene discussed is MET; the disease is esophageal squamous cell carcinoma.